Search
01/09/2024
Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study
Bobes, A, Tormo, M, Diaz-Beya, M, Beneit, P, Botella, C, Moreno, AF, Mayol, AS, Sangerman, MA, Bermejo, AY, Amigo, MD, Labrador, J, Guinon, AG, Garrido, A, Serrano, J, Polo, SV, Fortes, MG, Sayas, MJ, Bergua, JM, Olave, MT, Vall-Llovera, F, Bargay, J, Sanchez, MP, Boyero, RG, Diaz-Lopez, A, de la Fuente, A. Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study. Clinical Lymphoma Myeloma & Leukemia. 2024; 24DOI:. PMID:. IF:2.700(Q2/4D).
01/09/2024
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
Kirkegaard-Biosca, C, del Barrio-Tofiño, E, Villamarín, M, Larrosa, N, Campany, D, González-López, JJ, Ferrer, R, Viñado, B, Doménech, L, Sellarès-Nadal, J, Escolà-Vergé, L, Fernández-Hidalgo, N, Los-Arcos, I. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics-Basel. 2024; 13(9)DOI:10.3390/antibiotics13090874. PMID:39335047. IF:4.600(Q1/2D).
01/09/2024
Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles
Parladé, E, García-Leon, A, Voltà-Durán, E, Unzueta, U, Mangues, R, Casanova, I, Villaverde, A, Váquez, E. Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2024; 202DOI:10.1016/j.ejpb.2024.114410. PMID:39004320. IF:4.300(Q1/2D).
01/09/2024
Overview of Thigh and Leg Anatomical and Sonographic Landmarks in Rheumatic Patients
Balius, R, Pedret, C, Estrada-Alarcón, P, Corominas, H. Overview of Thigh and Leg Anatomical and Sonographic Landmarks in Rheumatic Patients. European Journal Of Rheumatology. 2024; 11DOI:10.5152/eurjrheum.2022.21131. PMID:36052637. IF:(Q/D).
01/09/2024
A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight
Mercader-García, P, Silvestre, JF, Navarro-Triviño, FJ, Giménez-Arnau, AM, Pastor-Nieto, MA, Cordoba-Guijarro, S, Melé-Ninot, G, Tous-Romero, F, González-Pérez, R, Ruiz-González, I, Sánchez-Pérez, J, Gática-Ortega, ME, Sánchez-Pedreño, P, Miquel-Miquel, J, Ortiz-Frutos, J, Carrascosa, JM, Serra-Baldrich, E, Sanz-Sanchez, T, Soria-Aledo, V, Carrillo, A, Borrego, L. A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight. CONTACT DERMATITIS. 2024; 91(3)DOI:10.1111/cod.14639. PMID:38965446. IF:4.600(Q1/1D).
01/09/2024
[Translated article] Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts.
Rivera-Díaz R, Carrascosa Carrillo JM, Alfonso Zamora S, Navarro Valdivieso JP, Muñoz Cabello B, Ros Abarca S, Soria de Francisco JM, Daudén Tello E. [Translated article] Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts.. Actas Dermo-Sifiliograficas. 2024; 115(8)DOI:10.1016/j.ad.2024.07.012. PMID:38972580. IF:(Q/D).